Calidi Biotherapeutics, Inc. Debt Instrument, Convertible, Conversion Ratio
Calidi Biotherapeutics, Inc. (CLDI) reported Debt Instrument, Convertible, Conversion Ratio of 42.00% for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-15.
Discontinued › Notes › Debt › Debt Instruments
us-gaap:DebtInstrumentConvertibleConversionRatio1 · last filed 2024-03-15
- Calidi Biotherapeutics, Inc. debt instrument, convertible, conversion ratio for fiscal 2023 was 42.00%.
| Period end | Debt Instrument, Convertible, Conversion Ratio 9 month | Debt Instrument, Convertible, Conversion Ratio 12 month |
|---|---|---|
| 2023-12-31 | 42.00% 10-K · filed 2024-03-15 | |
| 2023-09-30 | 41.00% 10-Q · filed 2023-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Silexion Therapeutics Corp (SLXN) | $0.001B | ||
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |